SMITHA PATIBANDLA: Open Payments
NPI 1154580918 · FORT WAYNE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$402 in 21 payments from 10 companies in 2025. Trend: 2023 $67 · 2024 $122 · 2025 $402
Food & beverage: $402
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $105 |
| Alkermes, Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 3 | $45 |
| Janssen Pharmaceuticals, Inc | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| ABBVIE INC. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
Products named: COBENFY, ARISTADA, UZEDY, REXULTI, HETLIOZ, VRAYLAR, INVEGA SUSTENNA, SPRAVATO.
Industry payments across IN — which companies pay providers there.
